Phakic intraocular lens (pIOL) implantation is an advanced refractive surgical procedure designed to correct significant visual errors by positioning a microscopic, custom-crafted lens inside the eye. Unlike traditional cataract surgery or refractive lens exchange, pIOL implantation leaves the natural crystalline lens intact. This preserves the eye's natural ability to change focus between near and far objects, a process known as accommodation.

The lens is typically placed in the posterior chamber, resting directly behind the iris and in front of the natural lens, or in the anterior chamber in front of the iris. The primary clinical goal of this procedure is to deliver clear, uncorrected distance vision while maintaining the structural integrity of the cornea. According to the American Academy of Ophthalmology (AAO Preferred Practice Pattern, 2022), phakic IOLs provide exceptional visual clarity and contrast sensitivity, particularly for patients with high degree refractive errors or thin corneas who are ineligible for laser-based procedures such as LASIK or PRK.

The pIOL implantation procedure is performed under strict sterile ophthalmic surgical standards. The patient receives topical anaesthetic drops and light oral or intravenous sedation if required. A specialized eyelid speculum holds the eye open. The surgeon makes a main micro-incision of 2.8 to 3.0 millimetres at the clear corneal periphery, along with one or two tiny side-port micro-incisions. A visco-elastic gel (ophthalmic viscosurgical device or OVD) is injected into the anterior chamber to maintain space and protect the corneal endothelium. The folded pIOL is loaded into an injector cartridge and smoothly inserted into the anterior chamber. The surgeon gently haptics (footplates) of the lens under the iris into the ciliary sulcus using a micro-manipulator tool. The visco-elastic gel is thoroughly washed out of the eye using automated irrigation-aspiration. Preservative-free antibiotic solution is injected, and the self-sealing micro-incisions are checked for watertight closure without sutures.

Phakic IOL implantation offers distinct evidence-based clinical benefits for appropriate refractive candidates:

• Preservation of Corneal Integrity: Because no corneal tissue is removed or reshaped, structural integrity and biomechanical strength are fully preserved (AAO PPP, 2022).
• Superior Visual Quality: Clinical studies show pIOLs deliver higher visual contrast sensitivity and lower optical aberrations compared to high-myopia LASIK or PRK treatments (Alfonso et al., 2019).
• Reversibility: The lens can be surgically removed or exchanged if the patient's visual prescription changes or if clinical complications arise.
• Preserved Accommodation: Preserves the natural crystalline lens, allowing young adult patients to maintain full natural close-up focusing capacity.
• Low Impact on Dry Eye: Micro-incisions do not disrupt major corneal nerves, significantly reducing the incidence of post-operative dry eye syndrome relative to corneal laser refractive surgery.
• Wide Range of Correction: Effectively treats extreme myopia and astigmatism outside the safe limits of corneal laser ablation.

Visual recovery after pIOL implantation is typically rapid, with many patients achieving functional vision within 24 to 48 hours. Patients must follow a structured post-operative protocol to protect the eye during tissue healing:

• Days 1 to 3: Initial visual acuity is evaluated. Mild surface sensation or glare is common. Protective eye shields are worn during sleep. Anti-inflammatory and antibiotic eye drops are administered four times daily.
• Week 1: Most patients return to desk work and light routine activities. Strenuous exercise, heavy lifting (>10 kg), bending at the waist, and swimming are strictly avoided to prevent intraocular pressure spikes and infection.
• Month 1: Corneal micro-incisions seal completely. Complete evaluation of lens vault height and intraocular pressure is performed. Gentle exercise may resume.
• Months 3 to 12: Refractive stabilization is confirmed. Long-term monitoring begins, focusing on yearly endothelial cell counts and internal structural integrity checks (ESCRS Guidelines, 2021).

Phakic intraocular lens implantation addresses several moderate-to-severe refractive errors and structural eye conditions, including:

• High Myopia (Nearsightedness): Correction of severe short-sightedness ranging typically from -0.50 Dioptres (D) to -20.00 D.
• Hyperopia (Farsightedness): Correction of long-sightedness ranging from +0.50 D to +10.00 D.
• Myopic and Hyperopic Astigmatism: Correction of irregular corneal curvature up to +6.00 D using toric phakic intraocular lenses.
• Thin Corneas: Refractive correction in individuals whose corneal thickness is insufficient for laser tissue ablation (LASIK or PRK).
• Keratoconus (Stable): Visual correction in stable, non-progressive ectatic corneal conditions where laser surgery is contraindicated.
• Severe Dry Eye Syndrome: Visual rehabilitation for patients whose pre-existing dry eye disease makes corneal laser surgery clinically risky.

Preoperative preparation involves precise ocular measurements performed several weeks prior to surgery. Patients must stop wearing soft contact lenses for at least 1 week and rigid gas-permeable (RGP) lenses for at least 3 weeks prior to evaluation to allow the cornea to return to its natural shape. Specialized presurgical diagnostics include anterior segment OCT, corneal topography, endothelial cell specular microscopy, and optical biometry to measure anterior chamber depth (ACD) and white-to-white (WTW) corneal diameter. On the day of surgery, patients receive dilating drops and topical antibiotic prophylaxis. Fasting for 4 to 6 hours before the procedure may be required if mild intravenous sedation is planned.

Complications following pIOL implantation are uncommon but require explicit clinical oversight. Early risks include temporary elevation of intraocular pressure (IOP) due to retained OVD gel or acute pupillary block, manageable with pressure-lowering eye drops. Mid-to-long-term risks include anterior subcapsular cataract formation if the lens vault is inadequate (<250 micrometres), reported in 1% to 3% of cases over 5 years (Kohnen et al., 2022). Endothelial cell density (ECD) loss can occur if the lens is positioned too close to the corneal back surface; yearly monitoring ensures loss remains within normal age-related parameters (~0.6% annually). Other rare complications include intraocular infection (endophthalmitis, <0.05%), lens dislocation, persistent halos or glare, and low-grade iridocyclitis (uveitis). Toxic anterior segment syndrome (TASS) is an extremely rare sterile inflammatory reaction.

The clinical pathway for phakic IOL implantation spans detailed diagnostic evaluation, precise surgical execution, and structured post-operative monitoring:

• Pre-Procedure Evaluation: High-resolution anterior segment imaging, including anterior segment optical coherence tomography (AS-OCT) and corneal ultrasound pachymetry, measures the internal dimensions of the eye. Specialist clinicians evaluate endothelial cell density (ECD) using specular microscopy to confirm corneal health and rule out pre-existing ocular conditions.
• Procedure Day: Performed as an outpatient procedure under local topical anaesthesia, the eye is numbed with drops. A micro-incision measuring approximately 2.8 to 3.0 millimetres is made at the clear corneal edge. The flexible lens is folded, injected into the eye, and carefully unfolded into position behind the iris. The procedure takes approximately 15 to 20 minutes per eye.
• Immediate Recovery: Intraocular pressure (IOP) is monitored 2 to 4 hours post-surgery to rule out acute pressure spikes. Patients return home the same day wearing protective eyewear, with prescribed antibiotic and anti-inflammatory eye drops.
• Long-Term Follow-Up: Structured follow-up visits occur at 1 day, 1 week, 1 month, 6 months, and annually thereafter. Routine long-term checks evaluate the lens positioning (vault height), intraocular pressure, and endothelial cell health.